
pmid: 15028616
Abstract: Moxonidine is a mixed a2‐adrenergic and imidazoline receptor agonist with an improved side effect profile compared to clonidine. Intrathecal (i.t.) moxonidine has been found to possess analgesic activity that, in contrast to the majority of a2‐adrenoceptor (a2AR) agonists, does not require activation of the a2AAR subtype, which mediates many of the side effects associated with a2AR use. In addition, moxonidine (i.t.) interacts in a synergistic manner with opioid agonists and this synergy is retained in neuropathic pain states. Moxonidine may therefore be clinically useful in the treatment of chronic neuropathic pain, either alone or as a coadjuvant with opioids.
Morphine, Receptors, Drug, Imidazoles, Pain, Drug Synergism, Anesthesia, Spinal, Analgesics, Opioid, Receptors, Adrenergic, alpha-2, Animals, Humans, Protein Isoforms, Imidazoline Receptors, Analgesia, Adrenergic alpha-Agonists
Morphine, Receptors, Drug, Imidazoles, Pain, Drug Synergism, Anesthesia, Spinal, Analgesics, Opioid, Receptors, Adrenergic, alpha-2, Animals, Humans, Protein Isoforms, Imidazoline Receptors, Analgesia, Adrenergic alpha-Agonists
| citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 14 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
